Literature DB >> 1324152

Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies.

J Imperato-McGinley1, R S Sanchez, J R Spencer, B Yee, E D Vaughan.   

Abstract

Studies were performed to compare the effects of 5 alpha-reductase inhibition and antiandrogen receptor blockade on differentiation of male internal and external genital structures and prostate in the rat. Dose-response studies were performed on male rats treated in utero during the period of sexual differentiation with either the potent 5 alpha-reductase inhibitor finasteride or the antiandrogen flutamide. The treated animals were raised to adulthood and killed, and genital structures were evaluated. Treatment with the 5 alpha-reductase inhibitor finasteride at a dose of 25 mg/kg.day resulted in significant feminization of the external genitalia. There was no further feminization of the genitalia at doses up to 300 mg/kg.day. Wolffian ductal differentiation occurred at all doses evaluated. Seminal vesicle weight, however, significantly decreased at 25 mg/kg.day, but without a further decrease at higher doses of the 5 alpha-reductase inhibitor. Vas deferens and epididymal weights were unchanged at all doses evaluated. There was a significant decrease in prostate size at 25 and 50 mg/kg.day, with no further decrease at higher doses. In flutamide-treated animals, complete feminization of the genitalia occurred at 24 mg/kg.day in all animals. At 18 mg/kg.day, Wolffian ductal differentiation occurred, but seminal vesicle weight was decreased. At dosages of 100, 200, and 300 mg/kg.day flutamide, the vas deferens was absent unilaterally or bilaterally, with small remnants of epididymal head and tail present. At dosages of 24 mg/kg.day and above, the prostate was absent. Studies with the 5 alpha-reductase inhibitor finasteride demonstrate the dependency of prostate and male external genital differentiation on dihydrotestosterone (DHT). However, unlike androgen receptor blockade with flutamide, finasteride did not totally abolish prostate differentiation or completely feminize the external genitalia, despite increasingly higher doses. Since there is no evidence of multiple 5 alpha-reductase isoenzymes to date in the rat, these results suggest that testosterone (T) can compensate for DHT to some degree at the level of the androgen receptor. Wolffian differentiation, however, was not affected by inhibition of DHT, demonstrating its T dependency, but seminal vesicle growth was impaired. Thus, inhibition of 5 alpha-reductase activity limits seminal growth potential in adulthood. Studies with the antiandrogen flutamide show that at doses significantly above that required to completely block prostate differentiation and cause genital feminization, Wolffian ductal differentiation is significantly impaired. Thus, higher doses of flutamide are needed to block the paracrine effect of T on the Wolffian ducts.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324152     DOI: 10.1210/endo.131.3.1324152

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  28 in total

1.  Differential regulation of testosterone vs. 5alpha-dihydrotestosterone by selective androgen response elements.

Authors:  P W Hsiao; T H Thin; D L Lin; C Chang
Journal:  Mol Cell Biochem       Date:  2000-03       Impact factor: 3.396

2.  Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone.

Authors:  S S Dadras; X Cai; I Abasolo; Z Wang
Journal:  Gene Expr       Date:  2001

3.  Expression in Escherichia Coli, Purification, and Functional Reconstitution of Human Steroid 5α-Reductases.

Authors:  Hwei-Ming Peng; Juan Valentín-Goyco; Sang-Choul Im; Bing Han; Jiayan Liu; Jie Qiao; Richard J Auchus
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

4.  The anti-androgen combination, flutamide plus finasteride, paradoxically suppressed LH and androgen concentrations in pregnant spotted hyenas, but not in males.

Authors:  Ned J Place; Elizabeth M Coscia; Nancy J Dahl; Christine M Drea; Kay E Holekamp; Janet F Roser; Cheryl L Sisk; Mary L Weldele; Stephen E Glickman
Journal:  Gen Comp Endocrinol       Date:  2010-10-29       Impact factor: 2.822

5.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

6.  Transcriptome analysis of the dihydrotestosterone-exposed fetal rat gubernaculum identifies common androgen and insulin-like 3 targets.

Authors:  Julia S Barthold; Yanping Wang; Alan Robbins; Jack Pike; Erin McDowell; Kamin J Johnson; Suzanne M McCahan
Journal:  Biol Reprod       Date:  2013-12-19       Impact factor: 4.285

Review 7.  Molecular determinants of sexual differentiation.

Authors:  J S Wiener; M Marcelli; D J Lamb
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 8.  Development of the external genitalia: perspectives from the spotted hyena (Crocuta crocuta).

Authors:  Gerald R Cunha; Gail Risbridger; Hong Wang; Ned J Place; Mel Grumbach; Tristan J Cunha; Mary Weldele; Al J Conley; Dale Barcellos; Sanjana Agarwal; Argun Bhargava; Christine Drea; Geoffrey L Hammond; Penti Siiteri; Elizabeth M Coscia; Michael J McPhaul; Laurence S Baskin; Stephen E Glickman
Journal:  Differentiation       Date:  2014-02-28       Impact factor: 3.880

9.  Identification in rats of a programming window for reproductive tract masculinization, disruption of which leads to hypospadias and cryptorchidism.

Authors:  Michelle Welsh; Philippa T K Saunders; Mark Fisken; Hayley M Scott; Gary R Hutchison; Lee B Smith; Richard M Sharpe
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

10.  Plasticity of basal cells during postnatal development in the rat epididymis.

Authors:  Winnie W C Shum; Eric Hill; Dennis Brown; Sylvie Breton
Journal:  Reproduction       Date:  2013-10-01       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.